Literature DB >> 20981509

Barth syndrome: an X-linked cardiomyopathy with a novel mutation.

Emtethal Aljishi1, Fouad Ali.   

Abstract

The authors report a 6 yr old boy with Barth syndrome who presented with cardiomyopathy, neutropenia and hypotonia. Urine gas chromatography showed high level of 3-methylglutaconic acid. The DNA of both the patient and the mother showed a heterozygous 3 bp deletion in exon 8 of the tafazzin gene. This abnormality involves the deletion of the bases TGA starting at cDNA nucleotide 891 (c891_893delTGA), resulting in the absence of glutamic acid at codon 202 from a highly conserved area of the tafazzin protein, consistent with the diagnosis of Barth syndrome. This is the first case report of Barth syndrome in Arab population emphasizing the importance of detailed investigations in cases of hereditary cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20981509     DOI: 10.1007/s12098-010-0222-y

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  7 in total

Review 1.  The failing heart.

Authors:  J A Towbin; N E Bowles
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

2.  Monolysocardiolipin in cultured fibroblasts is a sensitive and specific marker for Barth Syndrome.

Authors:  Michiel Adriaan van Werkhoven; David Ross Thorburn; Agi Kyra Gedeon; James Jonathon Pitt
Journal:  J Lipid Res       Date:  2006-07-27       Impact factor: 5.922

3.  Preliminary evidence for a cognitive phenotype in Barth syndrome.

Authors:  M M Mazzocco; R I Kelley
Journal:  Am J Med Genet       Date:  2001-09-01

4.  Cardiac and clinical phenotype in Barth syndrome.

Authors:  Carolyn T Spencer; Randall M Bryant; Jane Day; Iris L Gonzalez; Steven D Colan; W Reid Thompson; Julie Berthy; Sharon P Redfearn; Barry J Byrne
Journal:  Pediatrics       Date:  2006-07-17       Impact factor: 7.124

5.  An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes.

Authors:  P G Barth; H R Scholte; J A Berden; J M Van der Klei-Van Moorsel; I E Luyt-Houwen; E T Van 't Veer-Korthof; J J Van der Harten; M A Sobotka-Plojhar
Journal:  J Neurol Sci       Date:  1983-12       Impact factor: 3.181

Review 6.  X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update.

Authors:  Peter G Barth; Fredoen Valianpour; Valerie M Bowen; Jan Lam; Marinus Duran; Frédéric M Vaz; Ronald J A Wanders
Journal:  Am J Med Genet A       Date:  2004-05-01       Impact factor: 2.802

7.  Dilated cardiomyopathy due to type II X-linked 3-methylglutaconic aciduria: successful treatment with pantothenic acid.

Authors:  I Ostman-Smith; G Brown; A Johnson; J M Land
Journal:  Br Heart J       Date:  1994-10
  7 in total
  3 in total

Review 1.  Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.

Authors:  Hana M Zegallai; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2021-01-07       Impact factor: 3.396

Review 2.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

Review 3.  Successful management of Barth syndrome: a systematic review highlighting the importance of a flexible and multidisciplinary approach.

Authors:  Stacey Reynolds
Journal:  J Multidiscip Healthc       Date:  2015-07-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.